Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
Go back to Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C| HERCULES TECHNOLOGY GROWTH CAPITAL, Inc. (NYSE: HTGC) | Delayed: 15.23 -0.26 (1.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.49 | 52 Week High | $14.00 | |||
| Open | $15.44 | 52 Week Low | $9.92 | |||
| Day High | $15.65 | P/E | 8.65 | |||
| Day Low | $15.21 | EPS | $1.76 | |||
| Volume | 1,507,891 | |||||
